186 related articles for article (PubMed ID: 21889826)
1. [Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm].
Terrier B; Pol S; Thibault V; Gottenberg JE; Cacoub P;
Rev Med Interne; 2012 Jan; 33(1):4-12. PubMed ID: 21889826
[TBL] [Abstract][Full Text] [Related]
2. A Hospital-Based Analysis in the Department of Clinical Chemistry for the Patients with HBV Reactivation after Anti-Cancer or Immunosuppressive Therapy.
Matsuzaki T; Ohkubo K; Yuki M; Kawashima H; Matsunaga A
Rinsho Byori; 2015 Mar; 63(3):297-304. PubMed ID: 26524851
[TBL] [Abstract][Full Text] [Related]
3. A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
Bunyoz KI; Krarup H; Weis N
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260595
[TBL] [Abstract][Full Text] [Related]
4. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
[TBL] [Abstract][Full Text] [Related]
5. [Hepatitis B tests as screenings for the reactivation of HBV infection at Fukuoka University Hospital].
Matsuzaki T; Ohkubo K; Kawashima H; Matsunaga A
Rinsho Byori; 2011 Jun; 59(6):559-64. PubMed ID: 21815477
[TBL] [Abstract][Full Text] [Related]
6. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases.
Droz N; Gilardin L; Cacoub P; Berenbaum F; Wendling D; Godeau B; Piette AM; Dernis E; Ebbo M; Fautrel B; Le Guenno G; Mekinian A; Bernard-Chabert B; Costedoat-Chalumeau N; Descloux E; Michot JM; Radenne S; Rigolet A; Rivière S; Yvin JL; Thibault V; Thabut D; Pol S; Guillevin L; Mouthon L; Terrier B
Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1504-14. PubMed ID: 23436730
[TBL] [Abstract][Full Text] [Related]
7. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy.
Stine JG; Bass M; Ibrahim D; Khokhar OS; Lewis JH
South Med J; 2011 Dec; 104(12):781-8. PubMed ID: 22089354
[TBL] [Abstract][Full Text] [Related]
8. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.
Tran TT; Rakoski MO; Martin P; Poordad F
Aliment Pharmacol Ther; 2010 Jan; 31(2):240-6. PubMed ID: 19814747
[TBL] [Abstract][Full Text] [Related]
9. [Risk Management of HBV Reactivation: Construction of Check System].
Tanaka Y
Rinsho Byori; 2015 Sep; 63(9):1052-9. PubMed ID: 26731893
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis B reactivation following immunosuppressive therapy and screening adherence: a neglected problem?].
Borde JP; Kern WV; Becker J; Bertz H; Hübner J; Offensperger WB
Dtsch Med Wochenschr; 2012 Jul; 137(28-29):1458-62. PubMed ID: 22760404
[TBL] [Abstract][Full Text] [Related]
11. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
Sato K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
[TBL] [Abstract][Full Text] [Related]
12. [Reactivation of Hepatitis B Virus and Guidelines for Its Prevention].
Tsubouchi H
Rinsho Byori; 2015 Sep; 63(9):1046-51. PubMed ID: 26731892
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
15. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents.
Juan J; Feld JJ
Curr Opin Rheumatol; 2014 Jul; 26(4):395-403. PubMed ID: 24841230
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
19. [Screening practices for hepatitis B virus prior to viral reactivation risk therapies among different medical specialties. HEBRA Project].
García-Bengoechea M; Hernández-López C; Crespo J; Gea F;
Med Clin (Barc); 2012 Nov; 139(11):498-501. PubMed ID: 22982126
[No Abstract] [Full Text] [Related]
20. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.
Mindikoglu AL; Regev A; Schiff ER
Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1076-81. PubMed ID: 16861051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
